Eli Lilly’s Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

All NewsAugust 7, 2025

Eli Lilly shares fell after orforglipron’s Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent